Eli Lilly and Company (LLY)vsOrchestra BioMed Holdings Inc. (OBIO)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
OBIO
Orchestra BioMed Holdings Inc.
$3.80
-2.56%
HEALTHCARE · Cap: $239.94M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 194569% more annual revenue ($65.18B vs $33.48M). LLY leads profitability with a 31.7% profit margin vs -157.4%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
OBIO
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-65.7%
Fair Value
$2.45
Current Price
$3.80
$1.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 12120.0% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 21.8%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -109.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : OBIO
The strongest argument for OBIO centers on Revenue Growth, Debt/Equity, Operating Margin. Revenue growth of 12120.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : OBIO
The primary concerns for OBIO are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while OBIO is a hypergrowth play — different risk/reward profiles.
OBIO carries more volatility with a beta of 0.60 — expect wider price swings.
OBIO is growing revenue faster at 12120.0% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 37/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Orchestra BioMed Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?